Atossa Therapeutics Files 8-K with Board and Compensation Updates
Ticker: ATOS · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
Related Tickers: ATOS
TL;DR
ATOS 8-K: Board changes and compensation updates filed. Watch for governance shifts.
AI Summary
Atossa Therapeutics, Inc. filed an 8-K on March 12, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, with the earliest reported event date being March 9, 2024. The company is incorporated in Delaware and headquartered in Seattle, Washington.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Filings related to corporate governance and executive compensation can introduce uncertainty and affect investor sentiment.
Key Numbers
- 001-35610 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-4753208 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Seattle, Washington (location) — Principal Executive Offices
- March 09, 2024 (date) — Earliest event reported
- March 12, 2024 (date) — Date of Report
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific details of these changes are not provided in the excerpt.
What are the key updates regarding executive compensation?
The filing mentions 'Compensatory Arrangements of Certain Officers', suggesting updates or new arrangements, but the specifics are not detailed in the provided text.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that the company is making public disclosures to prevent selective disclosure of material non-public information, ensuring fair access for all investors.
What financial information is included in this filing?
The filing includes 'Financial Statements and Exhibits', but the excerpt does not provide details on the content of these statements.
When was Atossa Therapeutics, Inc. formerly known as Atossa Genetics Inc?
The date of the name change from Atossa Genetics Inc. to Atossa Therapeutics, Inc. was March 25, 2010.
Filing Stats: 710 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-12 08:30:09
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20240309.htm (8-K) — 44KB
- atos-ex99_1.htm (EX-99.1) — 16KB
- 0000950170-24-029671.txt ( ) — 178KB
- atos-20240309.xsd (EX-101.SCH) — 27KB
- atos-20240309_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. A copy of the Company's press release announcing the foregoing appointment is furnished hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibits Exhibit Number Description of Exhibit 99.1 Press release, dated March 12, 2024 104 Cover page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: March 12, 2024 By: /s/ Heather Rees Senior Vice President, Finance and Accounting